Genenta to Participate at Upcoming Investor Conferences
MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:
34th Annual ROTH Conference, Dana Point, California, U.S.
| Date: | March 13-15, 2022 |
| Format: | Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development |
| Management will also be available for one-on-one meetings |
Maxim Group LLC 2022 Virtual Growth Conference
| Date: | March 28, 2022 |
| Format: | Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development |
| Management will also be available for one-on-one meetings |
HC Wainwright Gene Therapy and Gene Editing Conference, virtual
| Date: | March 30, 2022 |
| Presenter: | Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development |
| Management will also be available for one-on-one meetings |
8th Annual LSX World Congress, London, UK and virtual
| Date: | May 10-11, 2022 |
| Format: | Keynote panel with Pierluigi Paracchi, CEO |
| CEO will also be available for one-on-one meetings |
Further information on these events may be found on the “News & Events” section of Genenta’s Investor website at https://ir.genenta.com/news-events/events.
About Genenta Science
Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). Temferon™, which is under investigation in a phase 1/2 clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which should induces a durable immune response not restricted to pre-selected tumor antigens nor type and aimed at reaching solid tumors, avoid systemic toxicity, some of the main unresolved challenges in immuno-oncology.
| Investor Relations – LifeSci Advisors: | Genenta Media/Investor Contact |
| Mary-Ann Chang, CFA | Tiziana Pollio |
| +44 7483 28 48 53 | +39 3482315143 |
| mchang@lifesciadvisors.com | tiziana.pollio@genenta.com |
